The rodent fountain of youth may not be filled with water, but with blood. A trio of new studies has discovered that the blood of young mice appears to reverse some of the effects of aging when put into the circulatory systems of elderly mice.
After combining the blood circulations of two mice by conjoining them – one old, the other young – researchers found dramatic improvements in the older mouse’s muscle and brain. After four weeks, stem cells in both those areas got a boost of activity and were better able to produce new neurons and muscle tissue.
They later discovered that injections of a special protein found abundantly in young blood – or even transfusions of whole young blood – gives the same advantages as sharing a blood supply.
Old mice who were injected with the protein or who received a blood transfusion navigated mazes faster and ran longer on treadmills. They easily outperformed their control peers, who were given only saline.
But for the young mice, getting old blood was a definite setback. When conjoined to an older mouse, the creation of new cells in the young mouse slowed down. Old blood effectively seemed to cause premature aging.
Two of the studies, both published online Sunday in the journal Science, came out of collaborations at the Harvard Stem Cell Institute that shared specimens of mice – one focused on muscle changes, and the other specialized in the brain. The third, published Sunday in Nature Medicine, came from a group of researchers from Stanford University and the University of California at San Francisco.
The Stanford group has been working in this area for a while, but we weren’t involved in their study, said Science study author and biologist Amy Wagers of the Harvard Stem Cell Institute. All of the studies are very consistent – the data are complementary and support one another.
Although initial results seem promising, questions still abound. Will it work on humans? What is the proper dosing? Do you need a constant supply of young blood to maintain the effects? Are there long-term consequences?
Nature Medicine study author and neuroscientist Tony Wyss-Coray of Stanford said he hopes to dive into human studies right off the bat. His new start-up company, Alkahest, is planning the first young-blood clinical trial at Stanford this year. Patients with Alzheimer’s disease will be given young blood, with researchers measuring their cognitive condition before and after.
Right now we can’t do anything for Alzheimer’s patients, and this seems so easy and simple, Wyss-Coray said.
The young mice in the three studies were the human equivalent of people in their 20s, so this would probably be the age range for donors used in a clinical trial. He said treating the big-picture issue of aging could in turn alleviate the burden of many diseases.
Most diseases that affect industrialized nations have a very strong aging component, and these are currently studied in isolation, Wyss-Coray said. But age is the key risk factor for all these diseases.
Judith Campisi, a biochemist at the Buck Institute for Research on Aging who was not involved in the studies, agreed that fundamental aging research is necessary and can have broad-ranging benefits.
If we understand the aging process in enough detail, we can begin to tackle the underlying mechanisms rather than treating one disease at a time, she said.